The Latest Breaking News from Obesity

Semaglutide, the drug behind the blockbuster weight-loss jabs Ozempic and Wegovy, does not slow cognitive decline in people with early-stage Alzheimer’s, according to two large new studies. The results close the door, for now, on hopes that a treatment for diabetes and obesity might also help protect the brain.

Social isolation kills. It increases your risk of death by 30% — roughly the same as smoking cigarettes and much worse than factors such as obesity and sedentary living.

Top scientists from have suggested that GLP-1s could have broader effects than just tackling obesity and diabetes.

It is expected that the tablet will be much cheaper than weight loss jabs.

French regulators have intensified their crackdown on the booming online trade in illicit weight-loss medicines, targeting platforms and sellers pushing unlicensed anti-obesity products.

Experts have linked high UPF consumption to higher risk of obesity, diabetes, heart disease, depression, and early death.

UPFs have been linked to poor health, including an increased risk of obesity, heart disease, cancer and early death

Novo Nordisk cuts Wegovy's price and commits fully to its upcoming weight-loss pill to stay competitive in the fast-growing obesity drug market.

Novo Nordisk's new $199 offer for Ozempic and Wegovy aims to improve access for obesity and diabetes treatments, but experts warn of potential serious side effects.